Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Longitudinal impact of conjugated pneumococcal vaccine (PCV13) on cytokine profile in different asthma phenotypes.

Kostinov Anton, Anna Konishcheva
ERJ Open Research 2022 8: 226; DOI: 10.1183/23120541.LSC-2022.226
Kostinov Anton
1Mechnikov Research Institute for Vaccines and Sera, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: amkostinov@gmail.com
Anna Konishcheva
1Mechnikov Research Institute for Vaccines and Sera, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: Administration of pneumococcal conjugated vaccine (PCV13) has been shown to reduce asthma exacerbation along with related effect on IgG/IgE-Abs to S. pneumoniae. Associated comprehensive related cytokine dynamics in BA endotypes are less clear. We aimed to determine the changes in Th1/Th2/Treg cytokines in 31 patients with different BA endotypes after PCV13 immunization.

Methods: ELISA level of IL-4, IL-6, IL-8, IL-10, IL-18, IFN-g, TNF-, MCP-1 measured in serum samples initially, 6 weeks, 6 and 12 months after vaccination. ACT –test and spirometric values have been measured at the same points.

Results: Under clustering of inflammatory BA phenotypes an increase in IFN-g (p<0,05) – up to 1,96 pg/ml [0,00; 2,6]was observed in allergic (Th2) BA 6 weeks from PCV13 administration. On the contrary, in patients with non-Th2 endotype, and asthma with obesity, lower values of IFN-g after 6 weeks (0,00 [0,00; 0,00], (p<0,05)) and 6 months (0,00 [0,00; 0.00], (p<0,05))have been detected. For late-onset Th2 asthma significant increase on IL-10 was observed after 12 months (3,12 [1,00; 8,22]) along with reduced serum IL-6 relative to other patients with late-onset non-Th2 asthma 6 months after vaccination (0,87 [0,66; 0,95](p<0,05).

Conclusion: Beneficial changes in proinflammatory/regulatory cytokines along with clinical effect are dependent from asthma phenotype and stable after 12 months from PCV13 administration especially in late-onset non-Th2 asthma indicating its immunomodulatory potential for further therapeutic strategies.

  • Immunology
  • Vaccination
  • Asthma - management

Footnotes

Cite this article as ERJ Open Research 2022; 8: Suppl. 8, 226.

This article was presented at the 2022 ERS Lung Science Conference, in session “Poster Session 2”.

This is an ERS Lung Science Conference abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2022
Previous
Back to top
Vol 8 Issue suppl 8 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Longitudinal impact of conjugated pneumococcal vaccine (PCV13) on cytokine profile in different asthma phenotypes.
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Longitudinal impact of conjugated pneumococcal vaccine (PCV13) on cytokine profile in different asthma phenotypes.
Kostinov Anton, Anna Konishcheva
ERJ Open Research Mar 2022, 8 (suppl 8) 226; DOI: 10.1183/23120541.LSC-2022.226

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Longitudinal impact of conjugated pneumococcal vaccine (PCV13) on cytokine profile in different asthma phenotypes.
Kostinov Anton, Anna Konishcheva
ERJ Open Research Mar 2022, 8 (suppl 8) 226; DOI: 10.1183/23120541.LSC-2022.226
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Phenotype and function of innate lymphoid cells in a murine model of impaired muco-ciliary clearance challenged with allergen
  • Monocyte migratory signatures identify acute and convalescent COVID-19 patients, and are associated with long COVID-19 symptoms
  • Polymeric immunoglobulin receptor and immunoglobulin A system in an eosinophilic mouse model of chronic rhinosinusitis
Show more Allergy and immunology

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society